Regarding yesterday's (23rd) hefty sell-off among Chinese biotech and pharmaceutical stocks, JPMorgan said in its report that it seemed to have been sparked by profit-taking decisions as a result of position adjustments rather than any fundamental deterioration.JPMorgan considered this pullback as a good entry opportunity to build positions in China's healthcare sector ahead of the next wave of catalyst-driven upside. The broker preferred the biotech and CXO (clinical trial service providers) sub-sectors, with INNOVENT BIO (01801.HK) -1.600 (-1.938%) Short selling $247.89M; Ratio 28.194% , SKB BIO (06990.HK) +20.600 (+4.541%) Short selling $111.06M; Ratio 18.469% , WUXI APPTEC (02359.HK) -1.000 (-0.763%) Short selling $91.84M; Ratio 23.617% , and WUXI XDC (02268.HK) +1.550 (+2.780%) Short selling $104.70M; Ratio 44.254% as its top picks. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)Related News UBS Cuts ALI HEALTH (00241.HK) TP to HKD3.6 as Higher Investment Reduces Earnings Visibility
AASTOCKS Financial News